Treat-to-target versus high-intensity statin treatment in patients with or without diabetes mellitus: a pre-specified analysis from the LODESTAR trial-Reference-Cited by-同舟云学术

Treat-to-target versus high-intensity statin treatment in patients with or without diabetes mellitus: a pre-specified analysis from the LODESTAR trial

Published:2023-10 Issue: Volume:64 Page:102227
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Lee Seung-Jun,Kang Woong Chol,Lee Jong-Young,Lee Jin-Bae,Yang Tae-Hyun,Yoon Junghan^ORCID,Lee Yong-Joon,Hong Sung-Jin,Ahn Chul-Min,Kim Jung-Sun^ORCID,Kim Byeong-Keuk,Ko Young-Guk,Choi Donghoon^ORCID,Hong Bum-Kee^ORCID,Jang Yangsoo,Hong Myeong-Ki^ORCID,Hong Myeong-Ki,Choi Donghoon,Ko Young-Guk,Kim Byeong-Keuk,Kim Jung-Sun,Ahn Chul-Min,Hong Sung-Jin,Lee Seung-Jun,Lee Yong-Joon,Hong Bum-Kee,Kwon Hyuck Moon,Kim Jong-Youn,Min Pil Ki,Yoon Young Won,Lee Byoung Kwon,Rim Se-Joong,Choi Eui-Young,CholKang Woong,Oh Pyung Chun,Lee Jong-Young,Lee Jin-Bae,Kim Kee Sik,Choi Ji Yong,Ryu Jae Kean,Hong Seung Pyo,Kim Chang Yeon,Yang Tae-Hyun,Cho Hyung-Jin,Yoon Junghan,Ahn Min-Soo,Ahn Sung Gyun,Lee Jun-Won,Son Jung-Woo,Jang Yangsoo,Yoon Hyuck-Jun,Lee Cheol Hyun,Hwang Jongmin,Cho Yun-Kyeong,Hur Seung-Ho,Han Seongwook,Nam Chang-Wook,Kim Hyoungseop,Park Hyoung-Seob,Kim In-Cheol,Cho Yun-Hyeong,Jeong Hyeon-Ju,Kim Jin-Ho,Lim Chewan,Suh Yongsung,Hwang Eui Seok,Lee Ji Hyun,Lee Sung Yun,Kwon Sung Uk,Kim Song-Yi,Park Keun-Ho,Ki Hyun Kuk

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines;Grundy;J Am Coll Cardiol,2019

2. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020

3. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023;ElSayed;Diabetes Care,2023

4. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial);Giugliano;Circulation,2018

5. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial;Sabatine;Lancet Diabetes Endocrinol,2017